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Background: Mounting reports on severe Plasmodium vivax malaria from across the globe have raised concerns
among the scientific community. However, the risk of P. vivax resulting in complicated malaria and mortality is not
as firmly established as it is with Plasmodium falciparum. This study was conducted to determine the severity
proportion and factors associated with severity in cases of vivax and falciparum malaria.
Methods: Adult patients microscopically diagnosed to have P. vivax/P. falciparum infections from the year
2007-2011 were evaluated based on their hospital records. Severe malaria was defined as per the World Health
Organization’s guidelines. Comparison was made across species and binary logistic regression was used to
determine risk factors of severity.
Results: Of 922 malaria cases included in the study, P. vivax was the largest (63.4%, 95% confidence interval (CI)
60.3-66.5%) infecting species, followed by P. falciparum (34.4%, 95% CI 31.3-37.5%) and their mixed infection (2.2%,
95% CI 1.3-3.2%). Severity in P. vivax and P. falciparum was noted to be 16.9% (95% CI 13.9-19.9%) and 36.3%
(95% CI 31.0-41.6%) respectively. Plasmodium falciparum had significantly higher odds [adjusted odds ratio (95% CI),
2.80 (2.04-3.83)] of severe malaria than P. vivax. Rising respiratory rate [1.29 (1.15-1.46)], falling systolic blood pressure
[0.96 (0.93-0.99)], leucocytosis [12.87 (1.43-115.93)] and haematuria [59.36 (13.51-260.81)] were the independent
predictors of severity in P. vivax. Increasing parasite index [2.97 (1.11-7.98)] alone was the independent predictor of
severity in P. falciparum. Mortality in vivax and falciparum malaria was 0.34% (95% CI -0.13-0.81%) and 2.21% (95% CI
0.59-3.83%), respectively. Except hyperparasitaemia and shock, other complications were associated (P < 0.05) with
mortality in falciparum malaria. Pulmonary oedema/acute respiratory distress syndrome was associated (P = 0.003)
with mortality in vivax malaria. Retrospective design of this study possesses inherent limitations.
Conclusions: Plasmodium vivax does cause severe malaria and mortality in substantial proportion but results in
much lesser amalgamations of multi-organ involvements than P. falciparum. Pulmonary oedema/acute respiratory
distress syndrome in P. vivax infection could lead to mortality and therefore should be diagnosed and treated
promptly. Mounting complications and its broadening spectrum in ‘not so benign’ P. vivax warrants global vigilance
for any probable impositions.
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The component of ‘severity’ or ‘complication’ in malaria
governs the choice of anti-malarial regimen and war-
rants intensive management. Plasmodium falciparum is
entrenched to be associated with life-threatening com-
plications, leading to widespread global annual mortality.
There has been a gradual increase in reports describing
sporadic atypical manifestations [1-4] to wide spectrum
severity [5-7] among Plasmodium vivax patients from
India and other parts of the globe. Of late this clamour
on the rising severity in P. vivax malaria has raised con-
cerns among the scientific community. However, the risk
of P. vivax resulting in complicated malaria and mortal-
ity is not firmly established [8]. The spectrum of malarial
severity may be extensively different among various pop-
ulations with diverse endemicity [9]. In India, there have
been few investigations to determine the spectrum of
severity and its associated factors with P. vivax in com-
parison to P. falciparum. In the existing literature from
India and elsewhere, studies have been either case re-
ports [1-3], or have lacked a denominator or compari-
son with other malaria species [7] or multivariate
logistic regression analysis [6,7,10], or have described
exiguous complications [11].
This study was aimed to perform a robust statistical
analysis to determine the spectrum of severity, its relative
proportions and factors associated with severity among
vivax and falciparum malaria and assess the validity of the
‘benign’ tag with P. vivax.Methods
Study design and patients
A study based on the records in a tertiary care hospital
was conducted from January 2007 to December 2011.
Initially patients’ data were abstracted onto physical
proforma and verified manually followed by construct-
ing an electronic database, its validation and analysis.
Patients of either gender, ≥18 years, hospitalized with
acute malaria, diagnosed by both quantitative buffy coat
and Leishman’s stained peripheral blood smears with
the presence of asexual forms of P. vivax, P. falciparum
or both, with or without gametocytes, were included.
All cases with, co-existent, non-malarial febrile illnesses
were excluded, Figure 1. Patients were managed by hos-
pital physicians as per their clinical judgement and na-
tional guidelines.Ethics statement
Prior to the commencement of the study, an approval of
the ethics committee of the Kasturba hospital, Manipal
University, Manipal, Karnataka, India was obtained. In
view of retrospective design of the study, obtaining indi-




Disease severity or complications were defined as per the
guidelines laid by the World Health Organization (WHO)
for the management of severe malaria in the year 2012
[12], with a modification for clinical jaundice/liver dysfunc-
tion, i e, rise in total bilirubin ≥2.5 mg/dL with simultan-
eous three-fold elevation in any serum aminotransferases
from their reference upper limits. Severity determinants
were restricted to cerebral malaria (impaired conscious-
ness, coma or multiple generalized convulsions within
24 hours), liver dysfunction, pulmonary oedema (PE) or
acute respiratory distress syndrome (ARDS) (radiological),
renal failure (serum creatinine >3 mg/dL), shock (systolic
blood pressure <80 mm Hg), spontaneous bleeding, hyper-
parasitaemia (parasite index >5%, i e, percentage of para-
sitized erythrocytes on Leishman-stained peripheral blood
smear), hypoglycaemia (blood sugar <40 mg/dL), respira-
tory distress (respiratory rate >32 beats/minute), metabolic
acidosis (plasma bicarbonate <15 mmol/L) and severe an-
aemia (haemoglobin <7 g/dL).
Dependent variable
Diagnosis of severe/complicated malaria was the primary
outcome. The entire cohort was classified into severe/com-
plicated and non-severe/uncomplicated malaria stratified
by the infecting species. Supportive requirements including
intensive care, more than seven days of hospitalization and
in-hospital mortality were secondary outcomes.
Statistical analysis
Categorical data were summarized as frequency and pro-
portions by severity category for each malaria species.
Proportions were examined using χ2 test or Fisher’s exact
test. Continuous variables were tested for normality using
the Kolmogorov–Smirnov test. Normally distributed con-
tinuous variables were reported as means with standard
deviations (SD), and compared by independent sample
t-test. Skewed variables were summarized as medians
with interquartile range (IQR) and compared by Mann
Whitney U test. Logistic regression analyses were per-
formed: 1) to determine the factors associated with disease
severity; and, 2) to determine the odds of supportive re-
quirements and mortality by disease severity and malaria
species. Multicollinearity was tested with variables, which
yielded a P-value of ≤0.1 in univariate analysis. Out of any
pair of variable showing collinearity, only one variable was
included into the multivariate logistic regression model.
All tests of significance were two-sided, with a P-value
of <0.05 indicating statistical significance. Data analysis
Figure 1 Flow chart of patients’ selection and distribution of severe malaria across species. RDT = Rapid diagnostic test.
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version 15.0 (SPSS, South Asia, Bangalore, India).Results
There were total 3,00,150 in-hospital admissions from
January 2007 to December 2011 including 1,79,842 males
and 1,20,308 females. A total of 1,191malaria patients
(0.40%) were hospitalized during the same period. Hos-
pital records of 47 (3.1%) patients remained inaccessible
and 222 (19.40%) cases were excluded in accordance with
pre-specified criteria. Remaining 922 eligible cases were
included for the study. Plasmodium vivax was the largest
(63.4%, 585/922) infecting malaria species followed by P.
falciparum (34.4%, 317/922) and their mixed infections
(2.2%, 20/922) (Figure 1). Due to a relatively smaller co-
hort of mixed infection, they could not be included in any
further analysis.Demographic, clinical and laboratory characteristics by
malaria species
Proportions of complicated cases among P. vivax and P.
falciparum were 16.9% (99/585) and 36.3% (115/317),
respectively (P <0.001). Figure 2 depicts the year-wise
proportions with rise and fall in complicated P. vivax
and P. falciparum cases included for the study. Male
preponderance (>70%) was observed across all compli-
cated malaria cohorts with no significant difference in
interspecies gender distribution (P = 0.26). The mean
duration of hospitalization in P. vivax and P. falcip-
arum was 5.3 ± 2.4 days and 7.4 ± 3.6 days, respectively
(P <0.001).Plasmodium vivax
Patients with complicated P. vivax were significantly older
(median age in years 40 vs. 26.5), P <0.001 (Additional
file 1). Duration of fever (P <0.001), frequency of pallor
(P = 0.02), icterus (P <0.01) and hepatomegaly (P = 0.02)
were significantly greater in complicated P. vivax cohort.
Systolic blood pressure (P = 0.04), axillary temperature
(P = 0.002), haemoglobin and platelet count (P <0.001)
were significantly lower in complicated P. vivax. There
were significant (P <0.001) elevations in leucocyte count,
erythrocyte sedimentation rate, levels of total and direct
bilirubin, serum aspartate aminotransferase, serum alka-
line phosphatase, blood urea and frequency of haematuria,
and haemoglobinuria in complicated P. vivax. Occurrence
of leucocytosis was also found to be associated with com-
plicated P.vivax malaria (P = 0.003).
Plasmodium falciparum
History of fever and headache was significantly less fre-
quent (P = 0.03) in complicated P. falciparum cohort.
Diarrhoea (P = 0.002), pallor and icterus (P <0.001),
splenomegaly (P = 0.03) and hepatomegaly (P = 0.01)
were more frequent in complicated P. falciparum. Re-
spiratory rate (P <0.001) and parasite index (P = 0.014)
were found to be significantly elevated in complicated P.
falciparum cohort. Haemoglobin (P <0.001) and platelet
count (P = 0.002) were significantly decreased in com-
plicated P. falciparum. Leucocyte count, haematuria,
haemoglobinuria, erythrocyte sedimentation rate, total
and direct bilirubin, aspartate aminotransferase, blood
urea, and serum creatinine had significantly (P <0.001)
increased in complicated P. falciparum. Occurrence of
Figure 2 Year-wise proportion and fluctuation in complicated Plasmodium vivax and Plasmodium falciparum cases included for the
study. Lower stack of each column represents number of total non-severe cases (bold font) for the respective year, upper stack of each column
represents number of severe cases (bold and italic font) for the respective year, above each column the bold and underlined font represents
number of mortality with respective species for the year.
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plicated P. falciparum malaria (P <0.001).
Patients’ treatment
Patients were initiated on anti-malarials only after con-
firmed microscopic diagnosis of malarial infections. Ma-
jority (75%) of P. falciparum, complicated P. vivax, and
mixed infections were treated with artesunate combin-
ation therapies, although 25% patients received standard
seven-day parenteral quinine in combination with doxy-
cycline/sulphadoxine-pyrimethamine till the year 2009.
The year 2010 witnessed an abrupt change in anti-malarial
treatment choice by clinicians, when quinine prescription
waned off and artesunate based combination therapy
remained the only choice for all cases of P. falciparum,
mixed infections and complicated P. vivax. Uncomplicated
P. vivax cases were treated with standard oral chloroquine
and primaquine regimen.
Until preliminary febrile investigations and culture re-
ports were obtained, empiric antibiotics were adminis-
tered to 6.6% (32/486), 8.4% (17/202) and 12.5% (1/8)
uncomplicated cases and to 9.1% (9/99), 17.4% (20/115)
and 25% (3/12) complicated cases of P. vivax, P. falcip-
arum and mixed malaria, respectively. Significantly high
(P = 0.003) proportion [14.2% (32/226)] of patients with
complicated malaria had received empiric antibiotics than
uncomplicated malaria [7.2% (50/696)].
Association of complications with mortality
Occurrence of cerebral malaria, liver dysfunction, se-
vere anaemia (P = 0.002), haemoglobinuria (P = 0.04)
and renal failure (P <0.001) was significantly higher in
P. falciparum than P. vivax. Hyperparasitaemia was sig-
nificantly (P = 0.002) associated with P. falciparum only.In P. vivax mortality was significantly associated with
PE/ARDS (P = 0.003) and respiratory distress (P = 0.001).
In P. falciparum except shock and hyperparasitaemia,
mortality was significantly associated with all the other se-
verity determinants (Table 1).
Both P. vivax patients succumbed due to ARDS and
respiratory distress. Out of seven P. falciparum patients
who died, only one succumbed with single complication,
i e, acute kidney injury despite dialysis. More than one
complication resulted in mortality in other fatalities with
P. falciparum. In both mixed malaria patients who died,
more than one complication was associated with mortal-
ity (Additional file 2). None of the patients who died had
any co-morbid aetiology.
Association of demographic, clinical and laboratory
factors with ‘complicated malaria’ as an outcome by
malaria species
With reference to P. vivax, the likelihood of developing
complicated malaria was significantly higher in P. falcip-
arum [odds ratio - 2.80 confidence interval - (2.04-3.83)].
In P. vivax, increasing respiratory rate [1.29 (1.15-1.46)],
falling systolic blood pressure [0.96 (0.93-0.99)], leucocyt-
osis [12.87 (1.43-115.93)] and haematuria [59.36 (13.51-
260.81)] were the independent predictors of complicated
malaria. In P. falciparum, rising parasite index [2.97 (1.11-
7.98)] was found to be the only independent predictor of
complicated malaria (Table 2).
Association of malaria severity as predictor for supportive
requirements and outcomes by malaria species
Compared to uncomplicated cohort, odds of blood trans-
fusion [9.80 (4.71-20.37)] and [10.70 (5.77-19.82)], more
than seven days of hospitalization [6.54 (3.83-11.18)] and
Table 1 Association of complications with mortality by malaria species












Cerebral malaria 4 (4) 0 1.00 20 (17.4) 4 (57.1) <0.001 0.002
Spontaneous bleeding 35 (35.4) 0 1.00 31 (27.0) 4 (57.1) 0.002 0.24
PE/ARDS 34 (34.3) 2 (100) 0.003 29 (25.2) 4 (57.1) 0.002 0.18
Shock 3 (3) 0 1.00 7 (6.1) 0 1.00 0.35
Liver dysfunction 11 (11.1) 0 1.00 33 (28.7) 4 (57.1) 0.003 0.002
Severe anaemia 6 (6.1) 0 1.00 25 (21.7) 4 (57.1) 0.001 0.002
Haemoglobinuria 6 (6.1) 0 1.00 17 (14.9) 2 (28.6) 0.049 0.04
Renal failure 6 (6.1) 0 1.00 38 (33) 5 (71.4) <0.001 <0.001
Respiratory distress 18 (18.2) 2 (100) 0.001 16 (13.9) 2 (28.6) 0.04 0.46
Metabolic acidosis 3 (3) 0 1.00 8 (7) 3 (42.9) <0.001 0.23
Hyperparasitaemia 0 0 ‡ 10 (8.7) 1 (14.3) 0.20 0.002
Hypoglycaemia 0 0 ‡ 2 (1.7) 2 (28.6) 0.001 0.50
*P - value obtained for difference in complications across malaria species by either chi - square or Fischer’s exact test, significant values, i e, <0.05 are shown in
bold face.
#P - value obtained for association of mortality with each complications by malaria species by either Chi-square or Fischer’s exact test, significant values, i e, <0.05
are shown in bold face.
‡Statistics could not be performed.
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care [4.19 (1.79-9.78)] and [1.91(1.47-2.48)] was more in
both complicated P. vivax and P. falciparum, respectively.
Among blood products transfused, odds of platelet [10.61
(4.31-26.13)] and [7.44 (3.60-15.60)] and packed red cells
[6.06 (1.49-24.75)] and [13.40 (4.84-37.11)] were signifi-
cantly higher in complicated P. vivax and P. falciparum,
respectively. Figure 3 depicts the proportions of support-
ive requirements in P. vivax and P. falciparum cohorts.
Mortality occurred in 2% (2/99), 6.1% (7/115) and 16.7%
(2/12) of severe P. vivax, P. falciparum and mixed infec-
tion, respectively. There was no difference in mortality ei-
ther across complicated groups of all species (P = 0.06) or
between P. vivax and P. falciparum (P = 0.18).
Discussion
The spectrum of severity and its determinants in adult
vivax malaria in comparison with falciparum malaria has
not been studied adequately. Also, the popular notion of
vivax malaria having only ‘benign’ course of infection
has been belied [1,3-7,11]. Present study aimed to deter-
mine the spectrum of severity and its relative contrast
between P. vivax and P. falciparum. This study encom-
passes the full spectrum (except ‘prostration’) of severity
determinants in accordance with the WHO criteria [12].
Although jaundice alone (total bilirubin >3 mg/dL) and
thrombocytopaenia are not severity criteria [12,13], they
occur most frequently with all forms of malaria and
greatly affect the clinical judgement. Thus, in order to
retain the relevance and applicability, liver dysfunction
was defined as a rise in total bilirubin ≥2.5 mg/dL withsimultaneous three-fold elevation in any serum amino-
transferases from their reference upper limits, which is
in agreement with contemporary WHO criteria [12].
Demographic, clinical and laboratory characteristics
Prolonged duration of fever gives an inference of delay
in diagnosis/onset of anti-malarial treatment, which could
be a potential reason for complications in complicated P.
vivax cohort. Absence of fever in a significant proportion
of complicated P. falciparum might have caused delayed
presentation, diagnosis and onset of anti-malarial treat-
ment thereby resulting in complicated malaria. Proportion
of complicated malaria across all species in the current
study varied substantially in comparison to other series
(Additional file 3) from diverse geography and endemicity
[9]. This variation in severity proportion is apparently also
due to lack of uniformity in the definition of severity
determinants and in number of determinants included
across all studies. Ironically, recent studies [6,10,14,15]
have defined severe malaria by severe anaemia (haemo-
globin <5 g/dL) and jaundice (total bilirubin >3 mg/dL)
with reference to outdated WHO guidelines [16,17],
while revised severity criteria include severe anaemia as
haemoglobin <7 g/dL and do not affirm the presence of
jaundice alone [12,13]. This non-uniformity in adoption
of severity criteria results in ambiguity, limits the
generalizability and use of study outcomes for comparison
with other series. Furthermore, variations in spectrum of
severity criteria adopted in studies impose difficulties for
researchers and policy makers to derive a reliable epi-
demiological cut-off/index. However, underlying genetic
Table 2 Logistic regression analysis with clinico-demographic and laboratory characteristics for determining the associated factor/s with complicated malaria





P-value* Odds ratio (95% CI) P-value* Adjusted Odds
ratio (95% CI)
P-value*
Malaria speciesŧ Reference 2.80 (2.04-3.83) <0.001
Demographic
Gender, male 0.49 (0.29-0.81) 0.005 0.37 (0.09-1.53) 0.17 0.87 (0.49-1.55) 0.63 §
Age, years (median, IQR) 1.03 (1.02-1.05) <0.001 # 1.01 (0.99 - 1.03) 0.11 §
Age categories
Up to 40 years Reference Reference Reference
Between 41 - 60 years 2.12 (1.31-3.42) 0.002 1.56 (0.49-4.97) 0.45 1.12 (0.69-1.84) 0..65 §
More than 60 years 2.40 (1.06-5.44) 0.035 2.59 (0.41-16.16) 0.31 1.64 (0.57-4.70) 0.36 §
History of fever 0.82 (0.09-7.37) 0.86 § 0.11 (0.01-0.94) 0.04 ‡
More than 3 days of fever 2.25 (1.35-3.77) 0.002 2.30 (0.62-8.55) 0.21 1.58 (0.88-2.85) 0.13 §
Headache 0.56 (0.36-0.87) 0.01 1.24 (0.44 - 3.49) 0.69 0.58 (0.36-0.92) 0.02 ‡
Diarrhoea 1.43 (0.56-3.63) 0.46 § 4.83 (1.94-12.04) 0.001 ‡
Pallor 1.97 (1.13-3.44) 0.02 # 4.35 (2.60-7.29) <0.001 #
Icterus 2.48 (1.51-4.08) <0.001 # 3.53 (2.18-5.71) <0.001 #
Splenomegaly 0.83 (0.52-1.32) 0.44 § 1.63 (1.02-2.61) 0.04 ‡
Hepatomegaly 1.80 (1.12-2.89) 0.015 0.55 (0.16-1.91) 0.35 1.86 (1.16-2.97) 0.01 0.03 (0.00-9.20) 0.23
Pulse rate (/min) 1.02 (1.001-1.03) 0.036 1.01 (0.97-1.04) 0.81 1.01 (0.99-1.02) 0.40 §
Respiratory rate (/min) 1.11 (1.06-1.17) <0.001 1.29 (1.15-1.46) <0.001 1.09 (1.04-1.13) <0.001 0.98 (0.66-1.46) 0.920
Systolic blood pressure (mmHg) 0.98 (0.96-0.99) 0.012 0.96 (0.93-0.99) 0.02 0.99 (0.98-1.01) 0.74 §
Diastolic blood pressure (mmHg) 0.98 (0.96-0.99) 0.02 # 0.99 (0.97-1.01) 0.34 §
Axillary temperature (°F)a 0.85 (0.74-0.97) 0.014 0.78 (0.56-1.09) 0.150 0.86 (0.74-1.01) 0.06 §
Parasite index (%) 1.66 (0.74-3.69) 0.22 § 1.33 (1.07-1.66) 0.01 2.97 (1.11-7.98) 0.03
Hemoglobin (gm/dL) 0.77 (0.70-0.85) <0.001 0.86 (0.67-1.11) 0.24 0.76 (0.69-0.84) <0.001 0.87 (0.39-1.94) 0.73
Leucocyte count/1,000/mm3 1.23 (1.12-1.34) <0.001 # 1.08 (1.01-1.15) 0.03 #
Leucocytosis ≥11,000/mm3 4.78 (1.79-12.74) 0.002 12.87 (1.43-115.93) 0.020 9.17 (3.63-23.17) <0.001 ‡
Leucopenia ≤4,000/mm3 0.72 (0.40-1.31) 0.28 § 0.36 (0.17-0.75) 0.006 0.48 (0.01-17.62) 0.690
Platelet count/10,000/mm3 0.95 (0.91-0.99) 0.012 # 0.97 (0.93-1.002) 0.06 §, #
Thrombocytopaenia ≤40,000/mm3 3.28 (1.99-5.41) <0.001 2.44 (0.67-8.88) 0.180 2.14 (1.30-3.52) 0.003 3.96 (0.17-91.31) 0.39
Erythrocyte sedimentation rate/10
(/1st hour)
















Table 2 Logistic regression analysis with clinico-demographic and laboratory characteristics for determining the associated factor/s with complicated malaria
(Continued)
Total bilirubin (mg/dL) 1.18 (1.09-1.28) <0.001 1.11 (0.93-1.32) 0.27 1.14 (1.09-1.19) <0.001 1.36 (0.93-1.98) 0.11
Direct bilirubin (mg/dL) 1.22 (1.11-1.35) <0.001 # 1.18 (1.11-1.25) <0.001 #
Aspartate aminotransferase (IU/L) 1.01 (1.01-1.02) <0.001 1.01 (0.99-1.02) 0.28 1.02 (1.01-1.02) <0.001 1.02 (0.98-1.06) 0.330
Alanine aminotransferase (IU/L) 1.01 (1.00-1.01) 0.06 §, # 1.01 (1.001-1.011) 0.02 #
Alkaline phosphatase (U/L) 1.01 (1.01-1.02) <0.001 1.00 (0.99-1.01) 0.21 1.01 (1.002-1.01) 0.002 0.98 (0.94-1.03) 0.43
Blood urea (mg/dL) 1.03 (1.02-1.05) <0.001 # 1.02 (1.01-1.03) <0.001 #
Serum creatinine (mg/dL) 2.78 (1.64-4.72) <0.001 2.20 (0.90-5.40) 0.09 3.51 (2.26-5.44) <0.001 #
Haematuria ≥ 0-5 RBCs/hpf 23.74 (9.74-57.83) <0.001 59.36 (13.51-260.81) <0.001 7.41 (2.99-18.33) <0.001 ‡
ŧUnivariate analysis considering malaria species as independent and complicated malaria as dependent variable.
§Univariate model did not yield significant association.
‡Statistics could not be computed.
*Significant P-value, i e, <0.05 are shown in bold face and odds ratios which did not overlap the null value, i e, 1 are shown in bold face.
aTo convert temperature to 0C=[0F-32]*5/9.
#Indicates collinearity, In P. vivax, Age - Age Category, Pallor - Haemoglobin and Erythrocyte sedimentation rate/10, Icterus - Total bilirubin, Systolic blood pressure - Diastolic blood pressure, Haemoglobin - Erythrocyte
sedimentation rate/10, Leucocyte count/1,000 - Leucocytosis, Platelet count/10,000 - Thrombocytopaenia, Total bilirubin - Direct bilirubin, Blood urea - Direct bilirubin and Serum creatinine, Aspartate aminotransferase - Alanine
aminotransferase. In P. falciparum, Pallor - Haemoglobin and Erythrocyte sedimentation rate/10, Icterus - Total and Direct bilirubin, Hemoglobin - Erythrocyte sedimentation rate/10, Leucocyte count/1000 - Leucocytosis,

















Figure 3 Association of supportive requirements by complicated malaria species. * = P <0.05.
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geography might also be associated with the variation in
the severity proportion across the globe, which requires
further exploration.Association of complications with mortality by malaria
species
Table 1 depicts spectrum of complications and outcome
by malaria species. Among severity determinants stud-
ied, P. falciparum resulted in every complication and,
except shock, the rest were clearly associated with mortal-
ity. Both hyperparasitaemia and hypoglycaemia did not
occur with P. vivax, suggesting increased parasite load to
be a reason for hypoglycaemia and parasite sequestration,
resulting in multiple organ involvement and mortality [12]
in P. falciparum but not in P. vivax. Pulmonary dysfunc-
tions viz respiratory distress, PE and ARDS turned out to
be the main reasons for mortality in P. vivax [6,15]. Evi-
dence [18-20] is mounting to support that sequestration
of P. vivax parasites in pulmonary microvasculature re-
sults in pulmonary dysfunction; however, further explor-
ation in this direction is certainly warranted. Further, on
the spectrum of severity (Additional file 2), P. vivax ap-
pears to result in relatively lesser amalgamations (up to
four) of complications in comparison with both P. falcip-
arum (up to seven) and mixed infections (up to six). There
is paucity of literature describing a comparable spectrum
of complications similar to the current study. Nadkar
et al. [6] have described up to four organs involved in both
P. vivax and P. falciparum. Sarkar et al. [7] have reported
up to eight complications and their four combinations
with P. vivax. Mohapatra et al. [10] have described up to
four complications in both P. falciparum and mixedinfections whereas as Tjitra et al. [11] have explained only
three complications and their combinations across P.
vivax, P. falciparum and mixed infection. Nonetheless, of
the existing studies, it is apparent that the spectrum of
complications in malaria is highly variable across the
globe. Further multicentric prospective study comprising
subjects across the globe, encompassing a uniform and
full spectrum of severity determinants, might lead to true
realization in this regard.
The present study is in concurrence with those
[6,14,15,21,22] having incremental mortality with in-
creasing organ dysfunctions in P. falciparum. Minimal
malaria mortality at the study hospital is on par with the
best worldwide [14,21,23].Factors associated with complicated malaria
In contrast with Tjitra et al. [11], P. falciparum was
found to be more likely to cause complicated malaria
than P. vivax. Rising respiratory rate, falling systolic blood
pressure, leucocytosis, and haematuria were independent
predictors of severe P. vivax malaria. These findings can
be used by clinicians as an index to decide intensive care
need for the better management and outcome of malaria
patients. Occurrence of leucocytosis is inconsistent in all
forms of malaria and depends on factors viz. severity of
disease, parasitaemia, host immunity and concomitant in-
fections. However, none of the study patients were having
bacteraemia or concurrent infections, as this was an exclu-
sion criterion of this study. Thus, either bacteraemia or
concurrent infection as a cause of leucocytosis is over-
ruled. Furthermore, low and unstable transmission in-
tensity of malaria in the catchment area of the hospital
might be responsible for non-immune status of patients
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sponse might have resulted in baseline leucocytosis. This
could be better understood by exploring parasite viru-
lence/immunogenic differences as well as human host
specific immune competence between severe and non-
severe cohorts. Rising parasite index alone was found to
be an independent predictor of severe P. falciparum.
However, parasite biomass has been advocated to be the
superior marker of severity than parasite index due to
massive sequestration in P. falciparum [24]. Interestingly,
despite most of the clinico-laboratory parameters having
significant association with disease severity in univariate
logistic regression analysis (Table 2), parasite index
counterpoised rest all in multivariate logistic regres-
sion analysis suggesting hyperparasitaemia to be the
determinant of pathophysiology in P. falciparum.
These differing independent predictors of severity
could indicate underlying pathophysiological differ-
ences between severe P. vivax and P. falciparum
infections.
Strengths and weaknesses of the study
The current study has remarkable strengths. This is a
unique study describing the full spectrum of severity de-
terminants in accordance with WHO contemporary cri-
teria [12] among P. vivax and P. falciparum malaria in
adult cohort. The study cohort is substantially large com-
prising >60% P. vivax, thereby provides a robust compari-
son with P. falciparum to challenge the ‘benign’ tag with
P. vivax. Determination of clinico-laboratory parameters
as risk factors for severity by multivariate logistic regres-
sion analysis provides simple, inexpensive and independ-
ent predictors of severity (rising respiratory rate, falling
systolic blood pressure, leucocytosis, haematuria and ris-
ing parasite index) which could be applied in routine clin-
ical practice. Retrospective design of the study possesses
inherent limitations. This study lacks confirmation of the
infecting species by polymerase chain reaction. Due to
retrospective study design any supportive evidence could
not be brought out to the involvement of immune re-
sponse resulting leucocytosis, thus this must be confirmed
and validated through future prospective study design.
Furthermore, coagulation parameters and venous bicar-
bonate levels were not tested in all patients as deemed
redundant by the treating physicians. Contribution of
pre-existing co-morbidities on disease severity could
not be described due to lack of sufficient data; however,
none of those expired had any co-morbid etiology. Data
on temporal onset of various complications and their
progression during illness were not captured. Thus, the
pathophysiology of progression of disease from infec-
tion to multi-organ involvement to final outcome could
not be discerned. Future studies must try to overcome
the limitations of this study.Conclusions
In adult malaria, the spectrum of severity may be exten-
sively different among various populations with diverse
endemicity. Although P. vivax does result in ‘severe mal-
aria’ and mortality in considerable proportion, the prob-
ability of such is significantly smaller than P. falciparum.
Furthermore, P. vivax results in much lesser amalgam-
ations of multi-organ involvement than P. falciparum and
mixed infections. Occurrence of PE/ARDS in P. vivax in-
fection could lead to mortality, therefore should be diag-
nosed and treated promptly. Rising respiratory rate, falling
systolic blood pressure, leucocytosis and haematuria were
the predictors of severity in P. vivax, whereas increasing
parasite index alone was the predictor of severity in
P. falciparum. By virtue of higher prevalence of P. vivax
and substantial proportion of broad spectrum severity as
manifested in the current study and other previous series,
it is imperative to be vigilant for any probable impositions
by P. vivax in addition to P. falciparum.
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Additional file 2: Spectrum of complications with outcome by
malaria species.
Additional file 3: Comparison of present study with other reports
describing complicated malaria in adults.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KS, KR and ABS: conception and design; KR and KS: acquisition of data; KS, KR
and AK: analysis and interpretation of data; KS and KR: drafting the
manuscript or revising it critically for important intellectual content; KS, KR,
AK, and ABS: final approval of the version to be published, and agree to be
accountable for all aspects of the work. All authors read and approved the
final manuscript.
Author details
1Department of Medicine, Kasturba Medical College, Manipal University,
Manipal 576104, Karnataka, India. 2Department of Community Medicine,
Kasturba Medical College, Manipal University, Manipal, India.
Received: 25 June 2014 Accepted: 29 July 2014
Published: 8 August 2014
References
1. Valecha N, Pinto RGW, Turner GDH, Kumar A, Rodrigues S, Dubhashi NG,
Rodrigues E, Banaulikar SS, Singh R, Dash AP, Baird JK: Histopathology of
fatal respiratory distress caused by Plasmodium vivax malaria. Am J Trop
Med Hyg 2009, 81:758–762.
2. Beg MA, Khan R, Baig SM, Gulzar Z, Hussain R, Smego RA Jr: Cerebral
involvement in benign tertian malaria. Am J Trop Med Hyg 2002,
67:230–232.
3. Lomar AV, Vidal JE, Lomar FP, Barbas CV, Matos GJ, Boulos M: Acute
respiratory distress syndrome due to vivax malaria: case report and
literature review. Braz J Infect Dis 2005, 9:425–430.
4. Sarkar S, Bhattacharya P: Cerebral malaria caused by Plasmodium vivax in
adult subjects. Indian J Crit Care Med 2008, 12:204–205.
5. Kochar DK, Saxena V, Singh N, Kochar SK, Kumar SV, Das A: Plasmodium
vivax malaria. Emerg Infect Dis 2005, 11:132–134.
Saravu et al. Malaria Journal 2014, 13:304 Page 10 of 10
http://www.malariajournal.com/content/13/1/3046. Nadkar MY, Huchche AM, Singh R, Pazare AR: Clinical profile of severe
Plasmodium vivax malaria in a tertiary care centre in Mumbai from June
2010-January 2011. J Assoc Physicians India 2012, 60:11–13.
7. Sarkar D, Ray S, Saha M, Chakraborty A, Talukdar A: Clinico-laboratory
profile of severe Plasmodium vivax malaria in a tertiary care centre in
Kolkata. Trop Parasitol 2013, 3:53–57.
8. World Health Organization: World Malaria Report. Geneva: World Health
Organization; 2013.
9. Marsh K, Forster D, Waruiru C, Mwangi I, Winstanley M, Marsh V, Newton C,
Winstanley P, Warn P, Peshu N, Pasvol G, Snow R: Indicators of
life-threatening malaria in African children. N Engl J Med 1995,
332:1399–1404.
10. Mohapatra MK, Dash LK, Barih PK, Karua PC: Profile of mixed species
(Plasmodium vivax and falciparum) malaria in adults. J Assoc Physicians
India 2012, 60:20–24.
11. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M,
Lampah DA, Price RN: Multidrug-resistant Plasmodium vivax associated
with severe and fatal malaria: a prospective study in Papua, Indonesia.
PLoS Med 2008, 5:e128.
12. World Health Organization: A practical handbook - Management of severe
malaria. 3rd edition. Geneva: World Health Organization; 2012.
13. World Health Organization: Guidelines for the treatment of malaria. 2nd
edition. Geneva: World Health Organization; 2010.
14. Abdallah TM, Abdeen MT, Ahmed IS, Hamdan HZ, Magzoub M, Adam I:
Severe Plasmodium falciparum and Plasmodium vivax malaria among
adults at Kassala Hospital, eastern Sudan. Malar J 2013, 12:148.
15. Limaye CS, Londhey VA, Nabar S: The study of complications of vivax
malaria in comparison with falciparum malaria in Mumbai. J Assoc
Physicians India 2012, 60:15–18.
16. World Health Organization: Severe and complicated malaria. Trans R Soc
Trop Med Hyg 1990, 84:S1–S65.
17. World Health Organization: Severe falciparum malaria. Trans R Soc Trop
Med Hyg 2000, 94:S1–S90.
18. Anstey NM, Handojo T, Pain MC, Kenangalem E, Tjitra E, Price RN,
Maguire GP: Lung injury in vivax malaria: pathophysiological evidence for
pulmonary vascular sequestration and posttreatment alveolar-capillary
inflammation. J Infect Dis 2007, 195:589–596.
19. Franke-Fayard B, Fonager J, Braks A, Khan SM, Janse CJ: Sequestration and
tissue accumulation of human malaria parasites: can we learn anything
from rodent models of malaria? PLoS Pathog 2010, 6:e1001032.
20. Anstey NM, Russell B, Yeo TW, Price RN: The pathophysiology of vivax
malaria. Trends Parasitol 2009, 25:220–227.
21. Zubairi AB, Nizami S, Raza A, Mehraj V, Rasheed AF, Ghanchi NK, Khaled ZN,
Beg MA: Severe Plasmodium vivax malaria in Pakistan. Emerg Infect Dis
2013, 19:1851–1854.
22. Krishnan A, Karnad DR: Severe falciparum malaria: an important cause of
multiple organ failure in Indian intensive care unit patients. Crit Care Med
2003, 31:2278–2284.
23. Marks M, Armstrong M, Walker D, Doherty T: Imported falciparum malaria
among adults requiring intensive care: analysis of the literature. Malar J
2014, 13:79.
24. Dondorp AM, Desakorn V, Pongtavornpinyo W, Sahassananda D, Silamut K,
Chotivanich K, Newton PN, Pitisuttithum P, Smithyman A, White NJ:
Estimation of the total parasite biomass in acute falciparum malaria
from plasma PfHRP2. PLoS Med 2005, 2:e204.
doi:10.1186/1475-2875-13-304
Cite this article as: Saravu et al.: Severity in Plasmodium vivax malaria
claiming global vigilance and exploration – a tertiary care centre-based
cohort study. Malaria Journal 2014 13:304.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
